These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27500181)

  • 1. Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia.
    Akhtar RS; Xie SX; Brennan L; Pontecorvo MJ; Hurtig HI; Trojanowski JQ; Weintraub D; Siderowf AD
    Mov Disord Clin Pract; 2016; 3(4):367-375. PubMed ID: 27500181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Correlates of Cerebral Amyloid Deposition in Parkinson's Disease Dementia: Evidence from a PET Study.
    Palermo G; Tommasini L; Aghakhanyan G; Frosini D; Giuntini M; Tognoni G; Bonuccelli U; Volterrani D; Ceravolo R
    J Alzheimers Dis; 2019; 70(2):597-609. PubMed ID: 31256138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury.
    Mitsis EM; Riggio S; Kostakoglu L; Dickstein DL; Machac J; Delman B; Goldstein M; Jennings D; D'Antonio E; Martin J; Naidich TP; Aloysi A; Fernandez C; Seibyl J; DeKosky ST; Elder GA; Marek K; Gordon W; Hof PR; Sano M; Gandy S
    Transl Psychiatry; 2014 Sep; 4(9):e441. PubMed ID: 25226550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.
    Clark CM; Pontecorvo MJ; Beach TG; Bedell BJ; Coleman RE; Doraiswamy PM; Fleisher AS; Reiman EM; Sabbagh MN; Sadowsky CH; Schneider JA; Arora A; Carpenter AP; Flitter ML; Joshi AD; Krautkramer MJ; Lu M; Mintun MA; Skovronsky DM;
    Lancet Neurol; 2012 Aug; 11(8):669-78. PubMed ID: 22749065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
    Vallabhajosula S
    Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR; Attems J; Ewers M
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
    Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
    J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional uptakes from early-frame amyloid PET and
    Myoraku A; Klein G; Landau S; Tosun D;
    Eur J Hybrid Imaging; 2022 Jan; 6(1):2. PubMed ID: 35039928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
    Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
    J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-β and τ biomarkers in Parkinson's disease-dementia.
    Buongiorno M; Compta Y; Martí MJ
    J Neurol Sci; 2011 Nov; 310(1-2):25-30. PubMed ID: 21764078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders.
    Irwin DJ; Hurtig HI
    J Alzheimers Dis Parkinsonism; 2018; 8(4):. PubMed ID: 30473927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuronal TNFα, Not α-Syn, Underlies PDD-Like Disease Progression in IFNβ-KO Mice.
    Villanueva EB; Tresse E; Liu Y; Duarte JN; Jimenez-Duran G; Ejlerskov P; Kretz O; Loreth D; Goldmann T; Prinz M; Issazadeh-Navikas S
    Ann Neurol; 2021 Nov; 90(5):789-807. PubMed ID: 34476836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
    Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
    Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies.
    Smith C; Malek N; Grosset K; Cullen B; Gentleman S; Grosset DG
    J Neurol Neurosurg Psychiatry; 2019 Nov; 90(11):1234-1243. PubMed ID: 31444276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.
    Irwin DJ; Grossman M; Weintraub D; Hurtig HI; Duda JE; Xie SX; Lee EB; Van Deerlin VM; Lopez OL; Kofler JK; Nelson PT; Jicha GA; Woltjer R; Quinn JF; Kaye J; Leverenz JB; Tsuang D; Longfellow K; Yearout D; Kukull W; Keene CD; Montine TJ; Zabetian CP; Trojanowski JQ
    Lancet Neurol; 2017 Jan; 16(1):55-65. PubMed ID: 27979356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.